Viewing Study NCT03089658


Ignite Creation Date: 2025-12-25 @ 12:21 AM
Ignite Modification Date: 2026-01-05 @ 2:13 AM
Study NCT ID: NCT03089658
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2019-10-09
First Post: 2017-03-20
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Sponsor: Merck KGaA, Darmstadt, Germany
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module